Shots:
- The US FDA has approved fexinidazole (PO, qd, 10days treatment) for both stages of Trypanosoma brucei gambiense form of sleeping sickness in patients aged >6yrs. & weighing at least 20 kg. The therapy has developed under the collaboration with DNDi, DRC, CAR & Sanofi
- Sanofi & partners are committed to access fexinidazole in all endemic countries for sleeping sickness because current treatment options for sleeping sickness are effective but troublesome for patients & health workers who live in remote areas
- Following the approval, Tropical disease PRV has been awarded to DNDi. Sanofi is committed to provide drug free-of-charge to WHO for distribution affected countries
Click here to read the full press release/ article | Ref: Sanofi | Image: Medcity News
The post Sanofi’s Fexinidazole Receives the US FDA’s Approval as the First Oral Treatment for Sleeping Sickness first appeared on PharmaShots.
